Search - tctmd.com

Displaying 881 - 900 of 1033

Sort: Relevancy | Date

News Industry News

BioFreedom™ Continues to Demonstrate Comparable Long-Term Safety and Efficacy to Conventional DES

October 31, 2013

Presentation TCT 2013

The Ongoing Saga of Short DAPT Therapy After DES: Navigating Device Evolution, New Pharmacotherapy, and Changing Clinical Practice Standards

Presenter: Roxana Mehran

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Presentation

Mini-Review of the Latest ACC/AHA and ESC Guidelines on DAPT and PCI

Presenter: Stephan Windecker

October 29, 2013

News Industry News

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

October 29, 2013

Presentation TCT 2013

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

Presenter: Eugenia Nikolsky

October 28, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

Presentation

Short- vs. Long-term Duration of DAPT in Patients Treated for In-Stent Restenosis

Presenter: Gianluca Campo

October 23, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Industry News

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

October 17, 2013

News Daily News

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

L.A. McKeown

October 11, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Daily News

ESC Consensus Statement Outlines Proper Role of Platelet Function Testing After PCI

September 30, 2013

News Daily News

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

Yael L. Maxwell

September 20, 2013

News Daily News

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Yael L. Maxwell

September 20, 2013

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Daily News

控制良好的华法林不会降低三联疗法出血风险

August 30, 2013

Advertisement

BioFreedom™ Continues to Demonstrate Comparable Long-Term Safety and Efficacy to Conventional DES

The Ongoing Saga of Short DAPT Therapy After DES: Navigating Device Evolution, New Pharmacotherapy, and Changing Clinical Practice Standards

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Mini-Review of the Latest ACC/AHA and ESC Guidelines on DAPT and PCI

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

Triple Therapy (DAPT Plus Chronic Oral Anticoagulation): Risks and Therapeutic Alternatives

Cre8, BioFreedom Polymer-Free DES Show Promise

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

Short- vs. Long-term Duration of DAPT in Patients Treated for In-Stent Restenosis

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

ESC Consensus Statement Outlines Proper Role of Platelet Function Testing After PCI

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

控制良好的华法林不会降低三联疗法出血风险

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content